Drug-eluting stent outcomes in diabetes

References

• Juutilainen A, Lehto S, Ronnemaa T, Pyorata K, Laakso M. Type 2 Diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 28(12), 2901–2907 (2005).
   PubMed Web of Science ®Google Scholar
• Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 108(12), 1527–1532 (2003).
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123, 798–813 (2011).
   PubMed Web of Science ®Google Scholar
• Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab. Vasc. Dis. Res. 2(1), 16–23 (2005).
   PubMedGoogle Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54(8), 2430–24305 (2005).
   PubMed Web of Science ®Google Scholar
• Vinik AI, Erbas T, Park TS et al. Platelet dysfunction in type 2 diabetes. Diabetes Care. 24(8), 1476–1485 (2001).
   PubMed Web of Science ®Google Scholar
• Ferroni P, Basili S, Falco A et al. Platelet activation in type 2 diabetes mellitus. J. Thromb. Haemost. 2(8), 1282–1291 (2004).
   PubMed Web of Science ®Google Scholar
• Kip KE, Faxon DP, Detre KM et al. Coronary angioplasty in diabetic patients: the national heart, lung, and blood institute percutaneous transluminal coronary angioplasty registry. Circulation 94(8), 1818–1825 (1996).
   Web of Science ®Google Scholar
• Mercado N, Boersma E, Wijns W et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J. Am. Coll. Cardiol. 38(3), 645–652 (2001).
   Web of Science ®Google Scholar
• Abaci A, Oguzhan A, Kahraman S et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99(17), 2239–2242 (1999).
   Google Scholar
• Abizaid A, Kornowski R, Mintz GS et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J. Am. Coll. Cardiol. 32(2), 584–589 (1998).
   Google Scholar
• Corpus RA, George PB, House JA et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J. Am. Coll. Cardiol. 43(1), 8–14 (2004).
   Google Scholar
• Morgan KP, Kapur A, Beatt KJ. Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention. Heart 90(7), 732–738 (2004).
   Google Scholar
• Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J. Am. Coll. Cardiol. 27(3), 528–535(1996).
   Google Scholar
• Kornowski R, Mintz GS, Kent KM et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 95(6), 1366–1369 (1997).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Kalidindi S et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J. Am. Coll. Cardiol. 52(4), 255–262 (2008).
   Google Scholar
• Kimura T, Kaburagi S, Tamura T et al. Remodeling of human coronary arteries undergoing coronary angioplastry or atherectomy. Circulation 96(2), 1218–1224 (1997).
   Google Scholar
• Iijima R, Ndrepepa G, Mehilli J et al. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am. Heart J. 154(4), 688–693 (2007).
   Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17), 2126–2130 (2005).
   PubMed Web of Science ®Google Scholar
• Park DW, Park SW, Park KH et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am. J. Cardiol. 98(3), 352–356 (2006).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. Antiplatelet therapy in type 2 diabetes mellitus. Curr. Opin. Endocrinol. Diabetes Obes. 14(2), 124–131 (2007).
   Google Scholar
• Montone RA, Sabato V, Sgueglia GA, Niccoli G. Inflammatory mechanisms of adverse reactions to drug-eluting stents. Curr. Vasc. Pharmacol. 11(4), 392–398 (2013).
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. The SIRIUS Investigators. N. Engl. J. Med. 349(14), 1315–1323 (2003).
   PubMed Web of Science ®Google Scholar
• Moussa I, Leon MB, Baim DS et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109(19), 2273–2278 (2004).
   PubMed Web of Science ®Google Scholar
• Sabate M, Jimenez-Quevedo P, Angiolillo DJ et al. DIABETES Investigators. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 112(14), 2175–2183 (2005).
   PubMed Web of Science ®Google Scholar
• Jimenez-Quevedo P, Hernando L, Gomez-Hospital JA, et al. Four years follow-up of DIABETES trial. J. Am. Coll. Cardiol. 53, A33 (2009).
   Google Scholar
• Chan C, Zambahari R, Kaul U et al. A randomized comparison of sirolimus-eluting verus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: the DECODE study. Catheter. Cardiovsc. Interv. 72(5), 591–600 (2008).
   Google Scholar
• Baumgart D, Klauss V, Baer F et al. SCORPIUS Study Investigators. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J. Am. Coll. Cardiol. 50(17), 1627–1634 (2007).
   PubMed Web of Science ®Google Scholar
• Maresta A, Varani E, Balducelli Met a. Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus [from the Italian Multicenter Randomized DESSERT Study]. Am. J. Cardiol. 101(11), 1560–1566 (2008).
   Google Scholar
• Stettler C, Allermann S, Wandel S et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 337, a1331 (2008).
   PubMedGoogle Scholar
• Hermiller JB, Raizner A, Cannon L et al. TAXUS-IV Investigators. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus. The TAXUS-IV trial. J. Am. Coll. Cardiol. 45(8), 1172–1179 (2005).
   PubMed Web of Science ®Google Scholar
• Kim MH, Hong SJ, Cha KS et al. Effect of paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. J. Interv. Cardiol. 21(3), 225–231 (2008).
   Google Scholar
• Maeng M, Jensen LO, Galloe AM et al. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am. J. Cardiol. 103(3), 345–349 (2009).
   Google Scholar
• Lee SW, Park SW, Kim YH et al. A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. J. Am. Coll. Cardiol. 52(9), 727–733 (2008).
   PubMedGoogle Scholar
• Tomai F, Reimers B, De Luca L et al. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study. Diabetes Care. 31(1), 15–19 (2008).
   Google Scholar
• Kufner S, de Waha A, Tomai F et al. A meta-analysis of specifically designed randomised trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. Am. Heart J. 162(4), 740–747 (2011).
   PubMed Web of Science ®Google Scholar
• Raber L, Wohlwend L, Wigger M et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trial. Circulation 123(24), 2819–2828 (2011).
   PubMed Web of Science ®Google Scholar
• Lee SW, Park SW, Kim YH et al. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial. JACC Cardiovasc. Interv. 4(3), 310–316 (2011).
   Google Scholar
• Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356(10), 989–997 (2007).
   PubMed Web of Science ®Google Scholar
• de Waha A, Dibra A, Kufner S et al. Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials. Clin. Res. Cardiol. 100(9), 561–570 (2011).
   Google Scholar
• Kirtane A, Ellis SG, Dawkins KD et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J. Am. Coll. Cardiol. 51(7), 708–715 (2008).
   Google Scholar
• Maeng M, Jensen LO, Tilsted HH et al. Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy). Am. J. Cardiol. 108(9), 1232–1237 (2011).
   Google Scholar
• Kirtane AJ, Patel R, O’Shaughnessy C et al. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc. Interv. 2(10), 967–976 (2009).
   Google Scholar
• Jang SJ, Park DW, Kim WJ et al. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and non-diabetic patients: 2-year subgroup analysis of the ZEST randomized trial. Catheter. Cardiovasc. Interv. 81(7), 1106–1114 (2013).
   Google Scholar
• Vardi M, Burke DA, Bangalore S et al. Long-term efficacy and safety of zotarolimus-eluting stent in patients with diabetes mellitus: Pooled 5-year results from the ENDEAVOR III and IV trials. Catheter. Cardiovasc. Interv. (2013) (Epub ahead of print).
   Google Scholar
• Sarno G, Lagerqvist B, Fröbert O et al. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish coronary angiography and angioplasty registry (SCAAR). Eur. Heart. J. 33(5) 606–613 (2012).
   PubMed Web of Science ®Google Scholar
• Yeung AC, Leon MB, Jain A et al. RESOLUTE US Investigators. Clinical evaluation of the Resolute zotarolimus eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. J. Am. Coll. Cardiol. 57(17), 1778–1783 (2011).
   PubMed Web of Science ®Google Scholar
• Silber S, Serruys PW, Leon MB et al. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program. JACC Cardiovasc. Interv. 6(4), 357–368 (2013).
   PubMed Web of Science ®Google Scholar
• GM Park, SW Lee, SW Park et al. Randomized comparison of zotarolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with DIABETES Mellitus ESSENCE-DIABETES II Trial. TCTAP, Seoul, Korea 22–25 April 2013.
   Google Scholar
• Serruys PW, Ruygrok P, Neuzner J et al. A randomised comparison of an everolimus eluting coronary stent with a paclitaxel eluting coronary stent:the SPIRIT II trial. EuroIntervention 2(3), 286–294 (2006).
   PubMedGoogle Scholar
• Claessen BE, Beijk MA, Legrand V et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circ. Cardiovasc. Interv. 2(4), 339–347 (2009).
   PubMed Web of Science ®Google Scholar
• Stone GW, Midei M, Newman W et al. SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299(16), 1903–1913 (2008).
   PubMed Web of Science ®Google Scholar
• Stone GW, Rizvi A, Newman W et al. SPIRIT IV Investigators. Everolimus eluting versus paclitaxel-eluting stents in coronary artery disease. N. Engl. J. Med. 362(18), 1663–1674 (2010).
   PubMed Web of Science ®Google Scholar
• Stone GW, Kedhi E, Kereiakes DJ et al. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 124(8), 893–900 (2011).
   PubMed Web of Science ®Google Scholar
• Grube E, Chevalier B, Guagliumi G et al. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs. the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am. Heart J. 163(5), 867–875, (2012).
   PubMed Web of Science ®Google Scholar
• Laynez A, Sardi G, Hauville C et al. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population. Catheter. Cardiovasc. Interv. 81(5), 759–765 (2013).
   Google Scholar
• Kim WJ, Lee SW, Park SW et al. ESSENCE-DIABETES Study Investigators. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial. Circulation 124(8), 886–892 (2011).
   PubMed Web of Science ®Google Scholar
• Jensen LO, Thayssen P, Junker A et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus and sirolimus-eluting stents (from the SORT OUT IV trial). Am. J. Cardiol. 110(11), 1585–1591 (2012).
   PubMed Web of Science ®Google Scholar
• Kufner S, Byrne RA, Mehilli J et al. Second-versus first-generation “Limus”-eluting stents in diabetic patients with coronary artery disease: A randomized comparison in setting of ISAR-TEST-4 trial. Catheter. Cardiovasc. Interv. (2013) (Epub ahead of print).
   Google Scholar
• Serruys PW, Silber S, Garg S et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N. Engl. J. Med. 363(2), 136–146 (2010).
   PubMed Web of Science ®Google Scholar
• von Birgelen C, Basalus MW, Tandjung K et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J. Am. Coll. Cardiol. 59(15), 1350–1361 (2012).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Fusaro M et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ 345, e5170 (2012).
   PubMedGoogle Scholar
• Kedhi E, Gomes ME, Lagerqvist B et al. Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register. JACC Cardiovasc. Interv. 5(11), 1141–1149 (2012).
   Google Scholar
• Hillegass WB, Patel MR, Klein LW et al. Long-term outcomes of older diabetic patients after percutaneous coronary stenting in the United States: a report from the national cardiovascular data registry, 2004 to 2008. J. Am. Coll. Cardiol. 60(22), 2280–2289 (2012).
   Google Scholar
• Linke A, Buszman P, Serruys P et al. 5-year clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with and without diabetes mellitus: a LEADERS sub-study. J. Am. Coll. Cardiol. 60, 17 (2012).
   Google Scholar
• Wijns W, Joly P, Kornowski R et al. Two years clinical outcomes of diabetic patients treated with a new generation drug-eluting stent. On behalf of NOBORI 2 Investigators. Euro PCR 2013. Paris, France 2013.
   Google Scholar
• Li Y, Han Y, Zhang L et al. Clinical efficacy and safety of biodegradable polymer-based sirolimus-eluting stents in patients with diabetes mellitus insight from the 4-year results of the create study. Catheter. Cardiovasc. Interv. 81(7), 1127–1133 (2013).
   Google Scholar
• de Waha A, Stefanini GG, King LA et al. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. Int. J. Cardiol. (2013) (Epub ahead of print).
   Google Scholar
• Carrié D, Berland J, Verheye S et al. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions. J. Am. Coll. Cardiol. 59(15), 1371–1376 (2012).
   PubMed Web of Science ®Google Scholar
• Carrié D. Cre8 Program Update. TCT 2012. Miami, Florida, USA 2013.
   Google Scholar
• Cassese S, Desch S, Kastrati A et al. Polymer-free sirolimus-eluting versus polymer-based paclitaxel-eluting stents: an individual patient data analysis of randomized trials. Rev. Esp. Cardiol. 66(6), 435–442 (2013).
   Google Scholar
• Desch S, Schloma D, Mobius-Winkler S et al. Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIAYukon trial. JACC Cardiovasc. Interv. 4(4), 452–459 (2011).
   Google Scholar
• Stiermaier T, Heinz A, Schloma D et al. Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial). Catheter. Cardiovasc. Interv. (2013) (Epub ahead of print).
   Google Scholar
• Van Geuns RJ. ABSORB EXTEND diabetic subset. Rotterdam EuroPCR Focus on BVS 2013.
   Google Scholar
• Hakeem A, Garg N, Bhatti S, Rajpurohit N, Ahmed Z, Uretsky BF. Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data. Am. Heart Assoc. 2(4), e000354 (2013).
   Web of Science ®Google Scholar
• Schwartz L, Bertolet M, Feit F et al. Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). Circ. Cardiovasc. Interv. 5(2), 166–173 (2012).
   Google Scholar
• Farooq V, Serruys PW, Garcia-Garcia HM et al. The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions: the SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial. J. Am. Coll. Cardiol. 61(3), 282–294 (2013).
   PubMed Web of Science ®Google Scholar
• Sarno G, Garg S, Onuma Y et al. ARTS-II Investigators. Impact of completeness of revascularization on the five-year outcome in percutaneous coronary intervention and coronary artery bypass graft patients (from the ARTS-II study). Am. J. Cardiol. 106(10), 1369–1375 (2010).
   Google Scholar
• Généreux P, Palmerini T, Caixeta A et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. J. Am. Coll. Cardiol. 59(24), 2165–2174 (2012).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ et al. TRITON-TIMI-38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 118(16), 1626–1636 (2008).
   PubMed Web of Science ®Google Scholar
• James S, Angiolillo DJ, Cornel JH et al. PLATO Study Group. Ticagrelor vs clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur. Heart J. 31(24), 3006–3016 (2010).
   PubMed Web of Science ®Google Scholar
• Nishio K, Sakurai M, Kusuyama T et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with Type 2 diabetes. Diabetes Care 29(1), 101–106 (2006).
   Google Scholar
• Choi D, Kim SK, Choi SH et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with Type 2 diabetes. Diabetes Care 27(11), 2654–2660 (2004).
   Google Scholar
• White WB, Cannon CP, Heller SR et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. The EXAMINE Investigators. N. Engl. J. Med. 369(14), 1327–1335 (2013).
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The SAVOR-TIMI 53 steering committee and investigators. N. Engl. J. Med. 369(14), 1317–1326 (2013).
   PubMed Web of Science ®Google Scholar
• Rydén L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J. (2013) (Epub ahead of print).
   Google Scholar
• Natali A, Vichi S, Landi P, Severi S, L’Abbate A, Ferrannini E. Coronary atherosclerosis in type II diabetes: angiographic findings and clinical outcomes. Diabetologia 43(5), 632–641 (2000).
   Google Scholar
• Waksman R. Are bioabsorbable vascular scaffolds really a breakthrough. TCT 2012. Miami, Florida, USA, 25 October 2012.
   Google Scholar
• Dibra A, Kastrati A, Mehilli J et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N. Engl. J. Med. 353(7), 663–670 (2005).
   PubMed Web of Science ®Google Scholar
• Urban P. Emerging DES: Polymer-Free Platforms. TCT Russia 2013. Moscow, Russia, 09 June 2013.
   Google Scholar